Insulet | PODD - Operating Profit


Insulet reported $122M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Abbott USD 1.85B 399M Mar/2026
Align Technology USD 178.05M 46.66M Mar/2026
AtriCure USD 526K 1.96M Mar/2026
Avanos Medical USD 8.9M 15.87M Mar/2026
Baxter International USD 66M 280.2M Mar/2026
Becton, Dickinson and Co. USD 627M 36M Mar/2026
Boston Scientific USD 1.05B 190M Mar/2026
Cardinal Health USD 861M 98M Mar/2026
Cooper Companies USD -31M 243.8M Mar/2026
Dexcom USD 255.3M 67.7M Mar/2026
Edwards Lifesciences USD 514.7M 144.4M Mar/2026
Eli Lilly USD 9.78B 792M Mar/2026
Globus Medical USD 164M 17.31M Mar/2026
ICU Medical USD 26.09M 770K Dec/2025
Inogen USD -7.79M 728K Sep/2024
Insulet USD 122M 24.3M Mar/2026
Integra LifeSciences USD 11.47M 54.54M Mar/2026
J&J USD 6.62B 1.03B Mar/2026
Medtronic USD 2.09B 354M Mar/2026
Merit Medical Systems USD 44.16M 10.04M Mar/2026
Roche Holding CHF 9.56B 3.8B Dec/2025
Solventum Corp USD 85M 20M Mar/2026
Stryker USD 1.1B 867M Mar/2026
Tandem Diabetes Care USD 8.29M 31.16M Dec/2025
Teleflex USD 37.03M 686K Mar/2026
West Pharmaceutical Services USD 177.1M 14.6M Mar/2026
Zimmer Biomet Holdings USD 395.1M 92.2M Mar/2026